Buy ELDN by Sep 6, 2026.

Eledone Pharmaceuticals (ELDN) just announced this study where 100% of people achieved insulin independence. It was only 12 patients but still the best result possible. Next step is probably a bigger study but could be a very good investment opportunity as the market capitalization is only $270 million. I feel like it has a ton of room to run and could be a buyout target.